Recent Advancements in the Atopic Dermatitis Mechanism
Open accessThe DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a recurrent, chronic, inflammatory, itchy skin disorder that affects up to 20% of the pediatric population and 10% of the adult population worldwide. Onset typically occurs early in life, and although cardinal disease features are similar across all ages, different age groups and ethnicities present distinct clinical characteristics. The disease imposes a significant burden in all health-related quality of life domains, both in children and adults, and a substantial economic cost both at individual and national levels. The pathophysiology of AD includes a complex and multifaceted interplay between the impaired dysfunctional epidermal barrier, genetic predisposition, and environmental contributors, such as chemical and/or biological pollutants and allergens, in the context of dysregulated TH2 and TH17 skewed immune response. Regarding the genetic component, the loss of function mutations encoding structural proteins such as filaggrin, a fundamental epidermal protein, and the more recently identified variations in the epidermal differentiation complex are well-established determinants resulting in an impaired skin barrier in AD. More recently, epigenetic factors have facilitated AD development, including the dysbiotic skin microbiome and the effect of the external exposome, combined with dietary disorders. Notably, the interleukin (IL)-31 network, comprising several cell types, including macrophages, basophils, and the generated cytokines involved in the pathogenesis of itch in AD, has recently been explored. Unraveling the specific AD endotypes, highlighting the implicated molecular pathogenetic mechanisms of clinically relevant AD phenotypes, has emerged as a crucial step toward targeted therapies for personalized treatment in AD patients. This review aims to present state-of-the-art knowledge regarding the multifactorial and interactive pathophysiological mechanisms in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tobacco smoke, whether through active or passive exposure, delivers benzene to the skin, which interferes with the inhibitory ability of TREG cells to secrete IL-10 and exert anti-inflammatory effects, which results in a higher prevalence of AD in children with relatives who smoke.”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The number of M2 macrophages expressing IL-31, CD68+ macrophages, and basophils in biopsies of skin affected by AD is positively related to TSLP and periostin expression in the epidermis of affected skin in patients with AD and also to disease severity.61”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, IL-4 and IL-13 constitute the main cytokines associated with the pathogenesis of early AD, as in addition to promoting type 2 inflammatory responses and recruiting eosinophils to the skin, they damage the epidermal barrier by suppressing the expression of structural proteins such as filaggrin, loricrin, and lipids, while concomitantly increasing collagen deposition in the dermis, which”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IL-18 acts on receptors (IL-18Rα) overexpressed on eosinophils in patients with AD and the histamine released by mast cells and basophils increases the expression of IL-18 on eosinophils by binding histamine with H2R and H4R, suggesting a relevant function of IL-18 and histamine in eosinophilic inflammation in AD.61”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated serum levels of IL-21 are observed in patients with AD, primarily produced by Th17 cells, which is associated with greater AD severity when compared to healthy controls so IL-21 directly promotes type 2 inflammation and suppresses Th1 responses by suppressing INFγ production.61”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [61]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, C. P. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0456 · Cited by 2,562 · cited 1×
“[108], highlighting the bidirectional interaction of the external environment and human health and disease, complementing the gene—environmental associations in the pathogenesis of allergic diseases.”
BackgroundTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“Subsequently, new therapeutic targets aiming at inhibiting IL-4R using monoclonal antibodies and JAK inhibitors are developed [137,138], while the inhibition of IL-13 using monoclonal antibodies attenuates the itch in AD [18,19].”
BackgroundLangan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A. M., Xu, A. Z., Tripathi, S. V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.006 · Cited by 1,092 · cited 3×
“…IL-4, IL-13, and IL-31, act through the TRP channel ankyrin transmembrane protein 1 (TRPA1) and the transient receptor potential (TRP) channel vallinoid 1 (TRPV1) by activating the calcium influx in the sensory fibers [134], while TSLP acts directly on the sensory nerves by binding to its receptor.”
BackgroundAkdis, C. A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00538-7 · Cited by 981 · cited 1×
“Microbiome dysbiosis in AD impairs immune responses and, in response to the ex-posome effects, contributes to the “leaking epithelium”, the subepithelial translocation of dysbiotic microbiota and opportunistic pathogens [82].”
BackgroundStänder, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2023911 · Cited by 756
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697 · cited 1×
“Importantly, the data indicate a restorative effect of dupilumab in AD by progressively ameliorating systemic and cutaneous abnormalities [63].”
BackgroundWollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19574 · Cited by 638 · cited 2×
“Subsequently, new therapeutic targets aiming at inhibiting IL-4R using monoclonal antibodies and JAK inhibitors are developed [137,138], while the inhibition of IL-13 using monoclonal antibodies attenuates the itch in AD [18,19].”
BackgroundMethodPathophysiology of atopic dermatitis: Clinical implications
Kim, J., Kim, B. E., & Leung, D. Y. M. (2019) · Allergy and Asthma Proceedings · doi:10.2500/aap.2019.40.4202 · Cited by 635 · cited 2×
“Furthermore, FLG and LOR, involucrin, and keratins 1,10 are downregulated in the presence of T2 inflammation cytokines, such as IL-4, IL-13, IL-22, and IL-31, in a process mediated by OVO-like 1 (OVOL1), an upstream transcription factor for these proteins [49,57].”
Background
Cited by
Update on the pathogenesis of atopic dermatitis.
Criado, P. R., Miot, H. A., Bueno-Filho, R., Ianhez, M., Criado, R. F. J., & de Castro, C. C. S. (2024) · Anais brasileiros de dermatologia · doi:10.1016/j.abd.2024.06.001 · Cited by 66
Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review
Torres, T. R., Mendes‐Bastos, P., Cruz, M. J., Duarte, B., Filipe, P., Lopes, M. J. P., & Gonçalo, M. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01352-y · Cited by 46
“This lipid deficiency further exacerbates barrier dysfunction and facil‑ itates the chronic inflammatory state observed in AD [42, 47].”
Advances in Atopic Dermatitis Treatment: From Pathogenesis to Natural Product‐Based Therapies
Fan, X., Liu, Z., Yang, W., Zhang, H., Zhong, H., Pang, Y., Ye, X., Wu, C., & Li, L. (2025) · Phytotherapy Research · doi:10.1002/ptr.70056 · Cited by 22
“The incidence rate of AD in infants is 11.3%–12.7% and 6.9%–7.6% in adults, respectively (Savva et al. 2024; Weins et al. 2024).”
InfluentialLivshits, G., & Kalinkovich, A. (2024) · Cells · doi:10.3390/cells13221899 · Cited by 16
Lin, Y., Zheng, L., Xu, Y., Wang, X., Li, J., Zheng, L., Liang, G., & Chen, L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01322 · Cited by 16
Metadata
- Authors
- Savva, M., Papadopoulos, N. G., Gregoriou, S., Katsarou, S., Papapostolou, N., Makris, M., & Xepapadaki, P.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Department of Dermatology and Venereology, Faculty of Medicine, National and Kapodistrian University of Athens, Andreas Sygros Hospital, 16121 Athens, Greece
- Corresponding author
- Savva, Maria
- ORCID
- Venue
- Frontiers in Bioscience-Landmark
- Publisher
- IMR Press
- Published
- 2024-02-22
- Volume
- 29
- Issue
- 2
- Pages
- 84-84
- ISSN
- 2768-6698 (ISSN-L)
- 2768-6701
- OpenAlex
- W4392106846
- Semantic Scholar
- 4c9790a5cd6a4e9f456e1c65c61b1fe6d8ec96fb
- Cited by
- 53
- References
- 159
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 9
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Frontiers in Bioscience-Landmark (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, pathophysiology, skin barrier dysfunction, filaggrin, epidermal differentiation complex, genetic susceptibility, epigenetics, skin microbiome, exposome, dietary factors, IL-31, pruritus, endotypes, pediatric atopic dermatitis, quality of life, economic burden
- MeSH terms
- Adult, Child, Dermatitis, Atopic, Humans, Quality of Life, Skin, Cytokines, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Advancements in the Atopic Dermatitis Mechanism. https://app.cochat.ai/papers/10.31083/j.fbl2902084
- The paper
- Savva, M., Papadopoulos, N. G., Gregoriou, S., Katsarou, S., Papapostolou, N., Makris, M., & Xepapadaki, P. (2024). Recent Advancements in the Atopic Dermatitis Mechanism. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2902084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.